"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients" (PHINK)
Primary Purpose
High-risk Leukemias
Status
Recruiting
Phase
Phase 1
Locations
Spain
Study Type
Interventional
Intervention
NK cells stimulated ex vivo with IL-15
Alloreactive NK cells
Sponsored by

About this trial
This is an interventional treatment trial for High-risk Leukemias
Eligibility Criteria
Inclusion Criteria:
- Patients of both sexes with age ≤ 21 years.
- Not having an identical HLA donor (family or non-family) available in the time needed for the donation of hematopoietic parents.
- Having a haploidenic donor available
- Diagnosis of high-risk hematological malignancy. This includes:
- i. High risk ALL in first complete remission (RC1);
- ii. ALL in second complete remission (RC2);
- iii. ALL in third complete remission (RC3) or later;
- iv. High risk AML in RC1;
- v. AML in RC2 or later;
- vi. Relapsed AML with <25% blasts in bone marrow;
- vii. AML related to previous treatments in CR> 12 months;
- viii. Primary or secondary myelodysplastic syndrome
- ix. NK cell leukemia, biphenotypic or undifferentiated in RC1 or later,
- x. Chronic myeloid leukemia (CML) in accelerated phase, in chronic phase with persistent molecular positivity, or with intolerance to tyrosine kinase inhibitors
- xi. Hodgkin's lymphoma in RC2 or later after failure of autologous TPH, or unable to mobilize hematopoietic progenitors for autologous TPH
- xii. Non-Hodgkin's lymphoma in RC2 or later after failure of autologous TPH, or unable to mobilize hematopoietic progenitors for autologous TPH
- xiii. Myelomonocytic juvenile leukemia.
- Positive pre-transplant evaluation
- i. Left ventricular ejection fraction > 40% or shortening fraction ≥ 25%;
- ii. Creatinine clearance (ACr) or glomerular filtration rate (TFG) ≥ 50 ml/min/1.73 m2
- iii. Forced Vital Capacity (FVC) ≥ 50% of predicted value or pulse-oximetry ≥ 92% if the patient cannot perform the pulmonary function tests;
- iv. Karnofsky or Lansky Index (depending on the patient's age) ≥ 50;
- v. Bilirubin ≤ 3 times the upper limit of normal for age
- vi. Alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal for age
- vii. Women who are not breastfeeding.
- viii. No uncontrolled bacterial, fungal, or viral infections at the time of inclusion.
- Women of childbearing potential must have a negative serum or urine pregnancy test performed within 14 days prior to trial inclusion and must agree to use highly effective contraceptive methods (diaphragms plus spermicide or male condom plus spermicide, oral contraceptive combined with a second method of contraceptive implant, injectable contraceptive, permanent intrauterine device, sexual abstinence, or partner with vasectomy) during study participation and for six months after the last trial visit. In the case of male patients with reproductive capacity, they must commit to using an appropriate barrier method for the duration of the study and for up to 6 months thereafter
Exclusion Criteria:
- Patients with an active infectious process or other serious underlying medical condition
- Patients who, according to the investigator's criteria, have a history of poor compliance with therapy.
- Patients who after a psycho-social evaluation are advised as not suitable for the procedure:
- i. Social-family situation that makes correct participation in the study impossible.
- ii. Patients with emotional or psychological problems secondary to the illness such as post-traumatic stress disorder, phobias, delusions, psychosis, with the need for support from specialists.
- iii. Evaluation of the involvement of family members in the health of the patient
- Inability to understand the information about the trial
- Received an investigational drug within 30 days prior to the start of therapy or within 5 half-lives of receiving an investigational drug, whichever is longer.
Sites / Locations
- Hospital Clínico Universitario de SantiagoRecruiting
- Hospital Universitario Central de AsturiasRecruiting
- Hospital de la Santa Creu i Sant PauRecruiting
- Hospital General Universitario Gregorio MarañónRecruiting
- Hospital Infantil Universitario Niño JeúsRecruiting
- Hospital Universitario La PazRecruiting
- Hospital Clínico Universitario Virgen de la Arrixaca
- Hospital Regional Universitario de Málaga (Carlos de Haya)
- Hospital Universitario Virgen del RocíoRecruiting
- Hospital Universitario La Fe
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
KIR mismatch aloreactive NK donor cells
NK cells stimulated ex vivo with IL-15 from KIR match donor
Arm Description
Three patients from each cohort will receive NK aloreactive cells from a KIR mismatch donor
Three patients in each cohort will receive ex vivo stimulated NK cells with IL-15 from a KIR match donor.
Outcomes
Primary Outcome Measures
Dose-limiting toxicity (TLD)
To determine dose-limiting toxicity (TLD) of a single infusion of aloreactive NK cells or ex vivo IL-15-stimulated NK cells after haploTPH in pediatric patients with high-risk leukemias.
Maximum tolerated dose (MTD)
To determine maximum tolerated dose (MTD) of a single infusion of aloreactive NK cells or ex vivo IL-15-stimulated NK cells after haploTPH in pediatric patients with high-risk leukemias.
Secondary Outcome Measures
Efficacy of post haploTPH NK cell therapy
The efficacy of post haploTPH NK cell therapy will be determined, comparing it with the historical cohort recently reported by GETH/GETMON in the incidence of graft failure, acute/chronic GVHD, viral reactivations (CMV, EBV, HHV-6, adenovirus, BKV), transplant-related mortality (TRM), and leukemia relapse.
Clinical evolution of patients
The clinical course of patients will be compared based on the dose of infused NK cells, KIR match vs. KIR mismatch NK cells, expansion, chimerism, and phenotypic and functional characteristics of the infused NK cells, and the speed and characteristics of immune reconstitution post haploTPH.
Monitor immune reconstitution and characterize NK cells
Immune reconstitution will be monitored by quantifying immunoglobulins at different times, and characterizing NK cells in patients, at a phenotypic and functional level, for 1 year after haploTPH
Full Information
NCT ID
NCT05304754
First Posted
January 12, 2022
Last Updated
March 30, 2022
Sponsor
Instituto de Investigación Hospital Universitario La Paz
1. Study Identification
Unique Protocol Identification Number
NCT05304754
Brief Title
"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients"
Acronym
PHINK
Official Title
Phase I / II Study on Infusion of Alloreactive or Stimulated Natural Killer Cells With IL-15 ex Vivo After Haploidentical Transplantation of Hematopoietic Progenitors in Pediatric Patients With Hematological Neoplasms
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
November 30, 2020 (Actual)
Primary Completion Date
June 2022 (Anticipated)
Study Completion Date
May 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Instituto de Investigación Hospital Universitario La Paz
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Phase I / II study on infusion of alloreactive or stimulated Natural Killer cells with IL-15 ex vivo after haploidentical transplantation of hematopoietic progenitors in pediatric patients with hematologic malignancies (PHINK
Detailed Description
Haploidentical hematopoietic stem cell transplantation (haploTPH) constitutes a highly complex but effective procedure for some hematologic malignancies high-risk pediatric patients in the absence of an identical HLA donor. Relapse Post-transplant leukemia is the main problem for survival. Just like reported different expert groups on haploTPH in adults and children, there is a determining role of Natural Killer (NK) cells in haploTPH as inducers powerful graft-versus-leukemia (EIcL) effect. The presence of NK cells allo-reactive is correlated with a lower relapse rate, in addition to favoring the graft, decrease graft versus recipient disease (GVHD) and decrease viral infections. This only occurs in half of the donor-recipient pairs, so that, in its absence, it is necessary to develop other strategies for activating the NK cells. In this sense, the investigational group has extensive experience in research translational with NK cells and is a pioneer in infusing ex vivo activated NK cells with IL-15.
The investigators propose a phase I / II clinical trial with dose escalation, multicenter, framed in the Spanish Group of Hematopoietic Transplantation / Marrow Transplant Bone in Children (GETH / GETMON), to determine the safety and efficacy of a post-haploTPH IL-15 alloreactive / stimulated NK cell infusion in children with malignant blood diseases. The investigators will monitor immune reconstitution, chimerism, Post-transplantation NK cell expansion, phenotype, and function.
Secondarily evaluate the effectiveness of therapy on the incidence of graft failure; EICR; viral reactivations; transplant-related mortality; and relapse of leukemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
High-risk Leukemias
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
18 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
KIR mismatch aloreactive NK donor cells
Arm Type
Active Comparator
Arm Description
Three patients from each cohort will receive NK aloreactive cells from a KIR mismatch donor
Arm Title
NK cells stimulated ex vivo with IL-15 from KIR match donor
Arm Type
Experimental
Arm Description
Three patients in each cohort will receive ex vivo stimulated NK cells with IL-15 from a KIR match donor.
Intervention Type
Biological
Intervention Name(s)
NK cells stimulated ex vivo with IL-15
Intervention Description
When patient and donor are KIR-HLA match, the patient submits all HLA class I molecules, or in the absence of any, your donor does not have this molecule, or having it lacks the corresponding KIR receiver. For more information detailed information on the product under investigation, reference is made to the Dossier of the Research Product (IMPD): PEI 09-008
Intervention Type
Biological
Intervention Name(s)
Alloreactive NK cells
Intervention Description
When the patient lacks the HLA class I molecule and his donor has this molecule and also the donor NK cells have the KIR receptor that recognizes the absence of the corresponding HLA class I ligand
Primary Outcome Measure Information:
Title
Dose-limiting toxicity (TLD)
Description
To determine dose-limiting toxicity (TLD) of a single infusion of aloreactive NK cells or ex vivo IL-15-stimulated NK cells after haploTPH in pediatric patients with high-risk leukemias.
Time Frame
52 weeks
Title
Maximum tolerated dose (MTD)
Description
To determine maximum tolerated dose (MTD) of a single infusion of aloreactive NK cells or ex vivo IL-15-stimulated NK cells after haploTPH in pediatric patients with high-risk leukemias.
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Efficacy of post haploTPH NK cell therapy
Description
The efficacy of post haploTPH NK cell therapy will be determined, comparing it with the historical cohort recently reported by GETH/GETMON in the incidence of graft failure, acute/chronic GVHD, viral reactivations (CMV, EBV, HHV-6, adenovirus, BKV), transplant-related mortality (TRM), and leukemia relapse.
Time Frame
Week 52
Title
Clinical evolution of patients
Description
The clinical course of patients will be compared based on the dose of infused NK cells, KIR match vs. KIR mismatch NK cells, expansion, chimerism, and phenotypic and functional characteristics of the infused NK cells, and the speed and characteristics of immune reconstitution post haploTPH.
Time Frame
Week 52
Title
Monitor immune reconstitution and characterize NK cells
Description
Immune reconstitution will be monitored by quantifying immunoglobulins at different times, and characterizing NK cells in patients, at a phenotypic and functional level, for 1 year after haploTPH
Time Frame
Week 52
10. Eligibility
Sex
All
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients of both sexes with age ≤ 21 years.
Not having an identical HLA donor (family or non-family) available in the time needed for the donation of hematopoietic parents.
Having a haploidenic donor available
Diagnosis of high-risk hematological malignancy. This includes:
i. High risk ALL in first complete remission (RC1);
ii. ALL in second complete remission (RC2);
iii. ALL in third complete remission (RC3) or later;
iv. High risk AML in RC1;
v. AML in RC2 or later;
vi. Relapsed AML with <25% blasts in bone marrow;
vii. AML related to previous treatments in CR> 12 months;
viii. Primary or secondary myelodysplastic syndrome
ix. NK cell leukemia, biphenotypic or undifferentiated in RC1 or later,
x. Chronic myeloid leukemia (CML) in accelerated phase, in chronic phase with persistent molecular positivity, or with intolerance to tyrosine kinase inhibitors
xi. Hodgkin's lymphoma in RC2 or later after failure of autologous TPH, or unable to mobilize hematopoietic progenitors for autologous TPH
xii. Non-Hodgkin's lymphoma in RC2 or later after failure of autologous TPH, or unable to mobilize hematopoietic progenitors for autologous TPH
xiii. Myelomonocytic juvenile leukemia.
Positive pre-transplant evaluation
i. Left ventricular ejection fraction > 40% or shortening fraction ≥ 25%;
ii. Creatinine clearance (ACr) or glomerular filtration rate (TFG) ≥ 50 ml/min/1.73 m2
iii. Forced Vital Capacity (FVC) ≥ 50% of predicted value or pulse-oximetry ≥ 92% if the patient cannot perform the pulmonary function tests;
iv. Karnofsky or Lansky Index (depending on the patient's age) ≥ 50;
v. Bilirubin ≤ 3 times the upper limit of normal for age
vi. Alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal for age
vii. Women who are not breastfeeding.
viii. No uncontrolled bacterial, fungal, or viral infections at the time of inclusion.
Women of childbearing potential must have a negative serum or urine pregnancy test performed within 14 days prior to trial inclusion and must agree to use highly effective contraceptive methods (diaphragms plus spermicide or male condom plus spermicide, oral contraceptive combined with a second method of contraceptive implant, injectable contraceptive, permanent intrauterine device, sexual abstinence, or partner with vasectomy) during study participation and for six months after the last trial visit. In the case of male patients with reproductive capacity, they must commit to using an appropriate barrier method for the duration of the study and for up to 6 months thereafter
Exclusion Criteria:
Patients with an active infectious process or other serious underlying medical condition
Patients who, according to the investigator's criteria, have a history of poor compliance with therapy.
Patients who after a psycho-social evaluation are advised as not suitable for the procedure:
i. Social-family situation that makes correct participation in the study impossible.
ii. Patients with emotional or psychological problems secondary to the illness such as post-traumatic stress disorder, phobias, delusions, psychosis, with the need for support from specialists.
iii. Evaluation of the involvement of family members in the health of the patient
Inability to understand the information about the trial
Received an investigational drug within 30 days prior to the start of therapy or within 5 half-lives of receiving an investigational drug, whichever is longer.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Antonio Pérez Martínez, Doctor
Phone
917277223
Ext
+34
Email
aperezmartinez@salud.madrid.org
Facility Information:
Facility Name
Hospital Clínico Universitario de Santiago
City
Santiago De Compostela
State/Province
A Coruña
ZIP/Postal Code
15706
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexandra Regueiro García, Doctor
Email
alexandra.regueiro.garcia@sergas.es
First Name & Middle Initial & Last Name & Degree
Alexandra Regueiro García, Doctor
Facility Name
Hospital Universitario Central de Asturias
City
Oviedo
State/Province
Asturias
ZIP/Postal Code
33011
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pilar M Palomo Moraleda, Doctor
Email
pilarpalomo@gmail.com
First Name & Middle Initial & Last Name & Degree
Pilar M Palomo Moraleda, Doctor
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
08041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabel Badell Serra, Doctor
Email
IBadell@santpau.cat
First Name & Middle Initial & Last Name & Degree
Isabel Badell Serra, Doctor
First Name & Middle Initial & Last Name & Degree
María Trabazo del Castillo, Doctor
Facility Name
Hospital General Universitario Gregorio Marañón
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cristina Beléndez Bieler, Doctor
Email
cristina.belendez@salud.madrid.org
First Name & Middle Initial & Last Name & Degree
Cristina Beléndez Bieler, Doctor
Facility Name
Hospital Infantil Universitario Niño Jeús
City
Madrid
ZIP/Postal Code
28009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marta González Vicent, Doctor
Email
martagonzalezvicent@gmail.com
First Name & Middle Initial & Last Name & Degree
Marta González Vicent, Doctor
Facility Name
Hospital Universitario La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio Pérez Martínez, Doctor
Phone
917277223
Ext
+34
Email
aperezmartinez@salud.madrid.org
First Name & Middle Initial & Last Name & Degree
Antonio Pérez Martínez, Doctor
First Name & Middle Initial & Last Name & Degree
David Bueno Sánchez, Doctor
First Name & Middle Initial & Last Name & Degree
Pilar Guerra García, Doctor
Facility Name
Hospital Clínico Universitario Virgen de la Arrixaca
City
Murcia
ZIP/Postal Code
30120
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
José L Fuster Soler, Doctor
Email
josel.fuster@carm.es
First Name & Middle Initial & Last Name & Degree
José L Fuster Soler, Doctor
Facility Name
Hospital Regional Universitario de Málaga (Carlos de Haya)
City
Málaga
ZIP/Postal Code
29010
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonia I Pascual Martínez, Doctor
Email
pascualmartinez5@hotmail.com
First Name & Middle Initial & Last Name & Degree
Antonia I Pascual Martínez, Doctor
Facility Name
Hospital Universitario Virgen del Rocío
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
José M Pérez Hurtado, Doctor
Email
mendozaj.perez.sspa@juntadeandalucia.es
First Name & Middle Initial & Last Name & Degree
José M Pérez Hurtado, Doctor
Facility Name
Hospital Universitario La Fe
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
José María Fernández Navarro
Email
chemafer@mac.com
12. IPD Sharing Statement
Citations:
PubMed Identifier
18606875
Citation
Ciceri F, Labopin M, Aversa F, Rowe JM, Bunjes D, Lewalle P, Nagler A, Di Bartolomeo P, Lacerda JF, Lupo Stanghellini MT, Polge E, Frassoni F, Martelli MF, Rocha V; Acute Leukemia Working Party (ALWP) of European Blood and Marrow Transplant (EBMT) Group. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008 Nov 1;112(9):3574-81. doi: 10.1182/blood-2008-02-140095. Epub 2008 Jul 7.
Results Reference
background
PubMed Identifier
11896281
Citation
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002 Mar 15;295(5562):2097-100. doi: 10.1126/science.1068440.
Results Reference
background
PubMed Identifier
15879158
Citation
Leung W, Iyengar R, Triplett B, Turner V, Behm FG, Holladay MS, Houston J, Handgretinger R. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol. 2005 May 15;174(10):6540-5. doi: 10.4049/jimmunol.174.10.6540.
Results Reference
background
PubMed Identifier
18176612
Citation
Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant. 2008 Mar;41(5):473-81. doi: 10.1038/sj.bmt.1705966. Epub 2008 Jan 7.
Results Reference
background
PubMed Identifier
18978746
Citation
Lang P, Handgretinger R. Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S54-9. doi: 10.1038/bmt.2008.285.
Results Reference
background
PubMed Identifier
21613256
Citation
Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Handgretinger R, Laver JH, Pui CH. High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood. 2011 Jul 14;118(2):223-30. doi: 10.1182/blood-2011-01-333070. Epub 2011 May 25.
Results Reference
background
PubMed Identifier
17442774
Citation
Handgretinger R, Chen X, Pfeiffer M, Mueller I, Feuchtinger T, Hale GA, Lang P. Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation. Ann N Y Acad Sci. 2007 Jun;1106:279-89. doi: 10.1196/annals.1392.022. Epub 2007 Apr 18.
Results Reference
background
PubMed Identifier
19664139
Citation
Moretta A, Pende D, Locatelli F, Moretta L. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clin Exp Immunol. 2009 Sep;157(3):325-31. doi: 10.1111/j.1365-2249.2009.03983.x.
Results Reference
background
PubMed Identifier
21126598
Citation
Ciurea SO, Mulanovich V, Jiang Y, Bassett R, Rondon G, McMannis J, de Lima M, Shpall EJ, Champlin RE. Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug;17(8):1169-75. doi: 10.1016/j.bbmt.2010.11.020. Epub 2010 Nov 30.
Results Reference
background
PubMed Identifier
19700662
Citation
Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 5;114(19):4283-92. doi: 10.1182/blood-2009-07-232454. Epub 2009 Aug 21.
Results Reference
background
PubMed Identifier
21486863
Citation
Distler E, Bloetz A, Albrecht J, Asdufan S, Hohberger A, Frey M, Schnurer E, Thomas S, Theobald M, Hartwig UF, Herr W. Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells. Haematologica. 2011 Jul;96(7):1024-32. doi: 10.3324/haematol.2010.037481. Epub 2011 Apr 12.
Results Reference
background
PubMed Identifier
15632206
Citation
Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005 Apr 15;105(8):3051-7. doi: 10.1182/blood-2004-07-2974. Epub 2005 Jan 4.
Results Reference
background
PubMed Identifier
19212329
Citation
Triplett BM, Horwitz EM, Iyengar R, Turner V, Holladay MS, Gan K, Behm FG, Leung W. Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2009 Jul;23(7):1278-87. doi: 10.1038/leu.2009.21. Epub 2009 Feb 12.
Results Reference
background
PubMed Identifier
28835441
Citation
Ciurea SO, Schafer JR, Bassett R, Denman CJ, Cao K, Willis D, Rondon G, Chen J, Soebbing D, Kaur I, Gulbis A, Ahmed S, Rezvani K, Shpall EJ, Lee DA, Champlin RE. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017 Oct 19;130(16):1857-1868. doi: 10.1182/blood-2017-05-785659. Epub 2017 Aug 23. Erratum In: Blood. 2018 Dec 27;132(26):2782.
Results Reference
background
PubMed Identifier
29247781
Citation
Wanquet A, Bramanti S, Harbi S, Furst S, Legrand F, Faucher C, Granata A, Calmels B, Lemarie C, Picard C, Chabannon C, Weiller PJ, Castagna L, Blaise D, Devillier R. Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2018 Mar;24(3):549-554. doi: 10.1016/j.bbmt.2017.11.042. Epub 2017 Dec 13.
Results Reference
background
PubMed Identifier
26341478
Citation
Perez-Martinez A, Fernandez L, Valentin J, Martinez-Romera I, Corral MD, Ramirez M, Abad L, Santamaria S, Gonzalez-Vicent M, Sirvent S, Sevilla J, Vicario JL, de Prada I, Diaz MA. A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. Cytotherapy. 2015 Nov;17(11):1594-603. doi: 10.1016/j.jcyt.2015.07.011. Epub 2015 Sep 1.
Results Reference
background
PubMed Identifier
20977942
Citation
Perez-Martinez A, Iyengar R, Gan K, Chotsampancharoen T, Rooney B, Holladay M, Ramirez M, Leung W. Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 May;17(5):598-607. doi: 10.1016/j.bbmt.2010.10.019. Epub 2010 Oct 25.
Results Reference
background
PubMed Identifier
29196968
Citation
Van Elssen CHMJ, Ciurea SO. NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect? Int J Hematol. 2018 Feb;107(2):151-156. doi: 10.1007/s12185-017-2379-x. Epub 2017 Dec 1.
Results Reference
background
PubMed Identifier
29477379
Citation
Vela M, Corral D, Carrasco P, Fernandez L, Valentin J, Gonzalez B, Escudero A, Balas A, de Paz R, Torres J, Leivas A, Martinez-Lopez J, Perez-Martinez A. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. 2018 May 28;422:107-117. doi: 10.1016/j.canlet.2018.02.033. Epub 2018 Feb 23.
Results Reference
background
PubMed Identifier
29542132
Citation
Fernandez L, Leivas A, Valentin J, Escudero A, Corral D, de Paz R, Vela M, Bueno D, Rodriguez R, Torres JM, Diaz-Almiron M, Lopez-Collazo E, Martinez-Lopez J, Perez-Martinez A. How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment? Transfusion. 2018 Jun;58(6):1340-1347. doi: 10.1111/trf.14573. Epub 2018 Mar 14.
Results Reference
background
Learn more about this trial
"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients"
We'll reach out to this number within 24 hrs